Please assess the completion status of the following clinical trial:

Trial Title: An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Signed written informed consent~2. Male or female patients aged \>=18 years (without upper limit of age)~3. ECOG performance status of 0 to 2~4. CML in chronic phase, with chronic phase defined as blasts \< 15% in blood and/or bone marrow and peripheral blood basophils \< 20% and platelets ≥ 100 G/L~5. Pretreatment with Imatinib with a treatment duration of at least 18 months at a dosage of 400 to 800 mg daily~6. Major molecular response (MMR) without molecular response ≥ 4.5 log (MR4.5), i.e. BCR-ABL\>0.0032% and ≤0.1% IS confirmed by central la-boratory at screening will be required for randomisation~7. Patients must have a serum Creatinine of ≤ 1.5 x ULN, SGOT ≤ 1.5 x ULN, total bilirubin ≤ 1.5 x ULN (except known M. Gilbert), and Lipase ≤ 1.5 x ULN~8. Women of child-bearing potential defined as sexually mature women who have not undergone a hysterectomy or who have not been naturally postmenopausal for at least 12 consecutive months, must have a negative serum pregnancy test during screening period. Male and fe-male patients of reproductive potential must agree to employ highly ef-fective methods of birth control throughout the study and for up to 3 months following discontinuation of study drug. Appropriate methods are e.g. a highly effective method of first choice, i.e. a method with a low failure rate (less than 1% per year) like sexual abstinence, com-bined oral contraceptives, implants, injectable, some Intra Uterine Devices (IUDs), vasectomized partner, in combination with a method of second choice like condom, diaphragm, or cup pessary with spermicidal foam/gel/film/cream/suppository.~Exclusion Criteria:~1. Any previous treatment for CML other than Hydroxyurea, Imatinib or Interferon alpha~2. Evidence of features of accelerated or blast phase at any time~3. Previous loss of hematologic or cytogenetic response~4. Concomitant medications known to be strong inducers or inhibitors of P450 Isoenzyme CYP3A4~5. Finding of a secondary BCR-ABL resistance mutation at any time~6. History of intolerance to Imatinib that required treatment interruption longer than 4 weeks (cumulative) or dose reductions to less than 400 mg daily for longer than 4 weeks (cumulative) during the last 12 months before informed consent~7. Patients who had prior allogeneic, syngeneic, or autologous bone mar-row transplant or stem cell transplant~8. Patients unwilling to or unable to comply with the planned therapeutic intervention or to comply with the study treatment visits including blood sample collection within the protocol~9. History of pancreatitis, chronic inflammatory diseases or autoimmune diseases~10. Patients who underwent solid organ transplantation~11. Impaired cardiac function, including any of the following:~    * History of or presence of complete left bundle branch block, right bundle branch block plus left anterior hemi block, bifascicular block in screening ECG~   * Use of a cardiac pacemaker~   * ST depression of \> 1mm in 2 or more leads and/or T wave inver-sions in 2 or more contiguous leads in screening ECG~   * Congenital Long QT Syndrome~   * QTc\> 450 msec in the screening ECG~   * QT prolonging concomitant medication~   * History of or presence of significant ventricular or atrial tachy-arrhythmia in screening ECG~   * History of or presence of clinically significant resting bradycardia (\< 50 beats per minute)~   * Myocardial infarction within 12 months prior to informed consent~   * Unstable angina diagnosed or treated during the past 12 months before informed consent~   * Other clinically significant heart disease (e.g., congestive heart fail-ure, uncontrolled hypertension, history of labile hypertension)~12. Known HIV and/or hepatitis B or C infection (testing is not mandatory)~13. Other malignancies within the past 3 years before informed consent except for adequately treated carcinoma of the cervix and basal or squamous cell carcinoma of the skin~14. Women who are pregnant or breast feeding~15. Male/female patients of reproductive potential unwilling to practice a highly effective method of birth control~16. History of noncompliance to medical regimens~17. Treatment with another investigational product during this study or during the last 30 days prior to informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Imatinib (Type: EXPERIMENTAL): Imatinib 400-800mg, daily, maximum 6 years
- Nilotinib (Type: ACTIVE_COMPARATOR): Nilotinib, 300mg, twice daily, maximum 6 years

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues